{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T01:42:43Z","timestamp":1784166163399,"version":"3.55.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T00:00:00Z","timestamp":1681776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T00:00:00Z","timestamp":1681776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>After completion of TB treatment patients may remain at risk of co-morbidity and mortality. We determined the survival and predictors of all-cause mortality after completing TB treatment among ART-experienced patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This was a retrospective cohort analysis of all ART experienced patients who completed TB treatment at a specialist HIV clinic in Uganda, between 2009 and 2014. The patients were followed for five years after TB treatment. We determined the cumulative probability of death, and predictors of mortality using Kaplan-Meier methods and Cox proportional hazard models, respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total 1,287 patients completed TB treatment between 2009 and 2014, of which 1,111 were included in the analysis. At TB treatment completion, the median age was 36 years (IQR: 31\u201342), 563 (50.7%) were males, and median CD4 cell count was 235 cells\/mL (IQR: 139\u2013366). The person-time at risk was 4410.60 person-years. The all-cause mortality rate was 15.42 (95% CI: 12.14\u201319.59) per 1000 person-years. The probability of death at five years was 6.9% (95%CI: 5.5- 8.8). In the multivariable analysis, CD4 count\u2009&lt;\u2009200 cells\/mL was a predictor of all-cause mortality (aHR\u2009=\u20091.81, 95%CI:1.06\u20133.11, p\u2009=\u20090.03) alongside history of retreatment (aHR\u2009=\u20092.12, 95%CI: 1.16\u20133.85, p\u2009=\u20090.01).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Survival post TB treatment in ART experienced PLHIV is reasonably good. Most deaths occur within two years after TB treatment completion. Patients with a low CD4 count and those with a history of retreatment have an increased risk of mortality which underscores the need for TB prophylaxis, detailed assessment, and close monitoring after completion of TB treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-023-08217-9","type":"journal-article","created":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T09:03:40Z","timestamp":1681808620000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Survival and predictors of mortality after completion of TB treatment among people living with HIV: a 5-year analytical cohort"],"prefix":"10.1186","volume":"23","author":[{"given":"Ivan","family":"Lumu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Musaazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aggrey","family":"Semeere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Handel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Castelnuovo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,18]]},"reference":[{"key":"8217_CR1","volume-title":"Global tuberculosis Report 2021","author":"WHO","year":"2021","unstructured":"WHO. Global tuberculosis Report 2021. Geneva: World Health Organisation; 2021."},{"key":"8217_CR2","doi-asserted-by":"crossref","unstructured":"Gelaw YA, Williams G, Soares Magalh\u00e3es RJ, Gilks CF, Assefa Y. HIV prevalence among tuberculosis patients in sub-saharan Africa: a systematic review and meta-analysis. AIDS Behav. 2019 Jun;23(6):1561\u201375.","DOI":"10.1007\/s10461-018-02386-4"},{"key":"8217_CR3","doi-asserted-by":"crossref","unstructured":"Bell LC, Noursadeghi M. Pathogenesis of HIV-1 and Mycobacterium tuberculosis co-infection. Nat Rev Microbiol. 2018 Feb;16(2):80\u201390.","DOI":"10.1038\/nrmicro.2017.128"},{"key":"8217_CR4","doi-asserted-by":"crossref","unstructured":"Musaazi J, Sekaggya-Wiltshire C, Kiragga AN, Kalule I, Reynolds SJ, Manabe YC, Castelnuovo B. Sustained positive impact on tuberculosis treatment outcomes of TB-HIV integrated care in Uganda. The International Journal of Tuberculosis and Lung Disease. 2019 Apr 1;23(4):514 \u2013 21.","DOI":"10.5588\/ijtld.18.0306"},{"key":"8217_CR5","doi-asserted-by":"crossref","unstructured":"Ismail I, Bulgiba A. Predictors of death during tuberculosis treatment in TB\/HIV co-infected patients in Malaysia. PLoS one. 2013 Aug 12;8(8): e73250.","DOI":"10.1371\/journal.pone.0073250"},{"key":"8217_CR6","doi-asserted-by":"crossref","unstructured":"Wondimu W, Dube L, Kabeta T. Factors affecting Survival Rates among Adult TB\/HIV co-infected patients in Mizan Tepi University Teaching Hospital, South West Ethiopia. Volume 12. HIV\/AIDS; 2020. p. 157. (Auckland, NZ).","DOI":"10.2147\/HIV.S242756"},{"key":"8217_CR7","doi-asserted-by":"crossref","unstructured":"Pasipanodya JG, Miller TL, Vecino M, Munguia G, Garmon R, Bae S, Drewyer G, Weis SE. Pulmonary impairment after tuberculosis. Chest. 2007 Jun 1;131(6):1817-24.","DOI":"10.1378\/chest.06-2949"},{"key":"8217_CR8","doi-asserted-by":"crossref","unstructured":"Byrne AL, Marais BJ, Mitnick CD, Lecca L, Marks GB. Tuberculosis and chronic respiratory disease: a systematic review. Int J Infect Dis. 2015 Mar;32(1):138\u201346.","DOI":"10.1016\/j.ijid.2014.12.016"},{"issue":"5","key":"8217_CR9","doi-asserted-by":"publisher","first-page":"930","DOI":"10.2105\/AJPH.2014.302431","volume":"105","author":"TL Miller","year":"2015","unstructured":"Miller TL, Wilson FA, Pang JW, Beavers S, Hoger S, Sharnprapai S, Pagaoa M, Katz DJ, Weis SE. Mortality hazard and survival after tuberculosis treatment. Am J Public Health. 2015;105(5):930\u20137.","journal-title":"Am J Public Health"},{"key":"8217_CR10","doi-asserted-by":"crossref","unstructured":"Fox GJ, Nguyen VN, Dinh NS, Nghiem LP, Le TN, Nguyen TA, Nguyen BH, Nguyen HD, Tran NB, Nguyen TL, Le TN. Post-treatment mortality among patients with tuberculosis: a prospective cohort study of 10 964 patients in Vietnam. Clinical Infectious Diseases. 2019 Apr 8;68(8):1359-66.","DOI":"10.1093\/cid\/ciy665"},{"key":"8217_CR11","doi-asserted-by":"crossref","unstructured":"Romanowski K, Baumann B, Basham CA, Khan FA, Fox GJ, Johnston JC. Long-term all-cause mortality in people treated for tuberculosis: a systematic review and meta-analysis. The Lancet Infectious Diseases. 2019 Oct 1;19(10):1129-37.","DOI":"10.1016\/S1473-3099(19)30309-3"},{"key":"8217_CR12","doi-asserted-by":"crossref","unstructured":"Ranzani OT, Rodrigues LC, Bombarda S, Minto CM, Waldman EA, Carvalho CR. Long-term survival and cause-specific mortality of patients newly diagnosed with tuberculosis in S\u00e3o Paulo state, Brazil, 2010\u201315: a population-based, longitudinal study. The Lancet Infectious Diseases. 2020 Jan 1;20(1):123 \u2013 32.","DOI":"10.1016\/S1473-3099(19)30518-3"},{"key":"8217_CR13","doi-asserted-by":"crossref","unstructured":"Zenner D, Abubakar I, Conti S, Gupta RK, Yin Z, Kall M, Kruijshaar M, Rice B, Thomas HL, Pozniak A, Lipman M. Impact of TB on the survival of people living with HIV infection in England, Wales and Northern Ireland. Thorax. 2015 Jun 1;70(6):566 \u2013 73.","DOI":"10.1136\/thoraxjnl-2014-206452"},{"key":"8217_CR14","doi-asserted-by":"crossref","unstructured":"Koenig SP, Kim A, Shepherd BE, Cesar C, Veloso V, Cortes CP, Padgett D, Crabtree-Ram\u00edrez B, Gotuzzo E, McGowan CC, Sterling TR. Increased mortality after tuberculosis treatment completion in persons living with human immunodeficiency virus in Latin America. Clin Infect Dis. 2020 Jun;24(1):215\u20137.","DOI":"10.1093\/cid\/ciz1032"},{"key":"8217_CR15","doi-asserted-by":"crossref","unstructured":"Hermans SM, Castelnuovo B, Katabira C, Mbidde P, Lange JM, Hoepelman AI, Coutinho A, Manabe YC. Integration of HIV and TB services results in improved TB treatment outcomes and earlier, prioritized ART initiation in a large urban HIV clinic in Uganda. Journal of acquired immune deficiency syndromes (1999). 2012 Jun 1;60(2): e29","DOI":"10.1097\/QAI.0b013e318251aeb4"},{"key":"8217_CR16","doi-asserted-by":"crossref","unstructured":"Odone A, Amadasi S, White RG, Cohen T, Grant AD, Houben RM. The impact of antiretroviral therapy on mortality in HIV positive people during tuberculosis treatment: a systematic review and meta-analysis. PloS one. 2014 Nov 12;9(11): e112017.","DOI":"10.1371\/journal.pone.0112017"},{"key":"8217_CR17","doi-asserted-by":"crossref","unstructured":"Johnson LF, May MT, Dorrington RE, Cornell M, Boulle A, Egger M, Davies MA. Estimating the impact of antiretroviral treatment on adult mortality trends in South Africa: A mathematical modelling study. PLoS medicine. 2017 Dec 12;14(12): e1002468.","DOI":"10.1371\/journal.pmed.1002468"},{"key":"8217_CR18","doi-asserted-by":"crossref","unstructured":"Brinkhof MW, Pujades-Rodriguez M, Egger M. Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PLoS ONE. 2009 Jun;4(4):e5790.","DOI":"10.1371\/journal.pone.0005790"},{"key":"8217_CR19","doi-asserted-by":"crossref","unstructured":"Shuldiner J, Leventhal A, Chemtob D, Mor Z. Mortality after anti-tuberculosis treatment completion: results of long-term follow-up. Int J Tuberc Lung Dis. 2016 Jan;20(1):43\u20138.","DOI":"10.5588\/ijtld.14.0427"},{"key":"8217_CR20","doi-asserted-by":"crossref","unstructured":"Pawlowski A, Jansson M, Sk\u00f6ld M, Rottenberg ME, K\u00e4llenius G. Tuberculosis and HIV co-infection.PLoS pathogens. 2012 Feb16;8(2):e1002464.","DOI":"10.1371\/journal.ppat.1002464"},{"key":"8217_CR21","doi-asserted-by":"crossref","unstructured":"Bisson GP, Zetola N, Collman RG. Persistent high mortality in advanced HIV\/TB despite appropriate antiretroviral and antitubercular therapy: an emerging challenge. Curr HIV\/AIDS Rep. 2015 Mar;12(1):107\u201316.","DOI":"10.1007\/s11904-015-0256-x"},{"key":"8217_CR22","doi-asserted-by":"crossref","unstructured":"Dangisso MH, Woldesemayat EM, Datiko DG, Lindtj\u00f8rn B. Long-term outcome of smear-positive tuberculosis patients after initiation and completion of treatment: A ten-year retrospective cohort study. PloS one. 2018 Mar 12;13(3): e0193396.","DOI":"10.1371\/journal.pone.0193396"},{"key":"8217_CR23","doi-asserted-by":"publisher","first-page":"826","DOI":"10.2471\/BLT.15.154161","volume":"93","author":"W Wang","year":"2015","unstructured":"Wang W, Zhao Q, Yuan Z, Zheng Y, Zhang Y, Lu L, Hou Y, Zhang Y, Xu B. Tuberculosis-associated mortality in Shanghai, China: a longitudinal study. Bull World Health Organ. 2015;93:826\u201333.","journal-title":"Bull World Health Organ"},{"key":"8217_CR24","doi-asserted-by":"crossref","unstructured":"Aung ZZ, Saw YM, Saw TN, Oo N, Aye HN, Aung S, Oo HN, Cho SM, Khaing M, Kariya T, Yamamoto E. Survival rate and mortality risk factors among TB\u2013HIV co-infected patients at an HIV-specialist hospital in Myanmar: a 12-year retrospective follow-up study. Int J Infect Dis. 2019 Mar;1:80:10\u20135.","DOI":"10.1016\/j.ijid.2018.12.008"},{"key":"8217_CR25","doi-asserted-by":"crossref","unstructured":"Meghji J, Lesosky M, Joekes E, Banda P, Rylance J, Gordon S, Jacob J, Zonderland H, MacPherson P, Corbett EL, Mortimer K. Patient outcomes associated with post-tuberculosis lung damage in Malawi: a prospective cohort study. Thorax. 2020 Mar 1;75(3):269 \u2013 78.","DOI":"10.1136\/thoraxjnl-2019-213808"},{"key":"8217_CR26","doi-asserted-by":"crossref","unstructured":"Lawn SD, Myer L, Edwards D, Bekker LG, Wood R. Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS (London, England). 2009 Aug 24;23(13):1717.","DOI":"10.1097\/QAD.0b013e32832d3b6d"},{"issue":"2","key":"8217_CR27","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1128\/CMR.00042-10","volume":"24","author":"CK Kwan","year":"2011","unstructured":"Kwan CK, Ernst JD. HIV and tuberculosis: a deadly human syndemic. Clin Microbiol Rev. 2011;24(2):351\u201376.","journal-title":"Clin Microbiol Rev"},{"key":"8217_CR28","doi-asserted-by":"crossref","unstructured":"Pettit AC, Giganti MJ, Ingle SM, May MT, Shepherd BE, Gill MJ, F\u00e4tkenheuer G, Abgrall S, Saag MS, Del Amo J, Justice AC. Increased non-AIDS mortality among persons with AIDS\u2010defining events after antiretroviral therapy initiation. J Int AIDS Soc. 2018 Jan;21(1):e25031.","DOI":"10.1002\/jia2.25031"},{"key":"8217_CR29","doi-asserted-by":"crossref","unstructured":"Huaman MA, Kryscio RJ, Fichtenbaum CJ, Henson D, Salt E, Sterling TR, Garvy BA. Tuberculosis and risk of acute myocardial infarction: a propensity score-matched analysis. Epidemiol Infect. 2017 May;145(7):1363\u20137.","DOI":"10.1017\/S0950268817000279"},{"key":"8217_CR30","doi-asserted-by":"crossref","unstructured":"Hakim J, Musiime V, Szubert AJ, Mallewa J, Siika A, Agutu C, Walker S, Pett SL, Bwakura-Dangarembizi M, Lugemwa A, Kaunda S. Enhanced prophylaxis plus antiretroviral therapy for advanced HIV infection in Africa.New England Journal of Medicine. 2017 Jul20;377(3):233\u201345.","DOI":"10.1056\/NEJMoa1615822"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08217-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-023-08217-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08217-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T09:05:39Z","timestamp":1681808739000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-023-08217-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,18]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["8217"],"URL":"https:\/\/doi.org\/10.1186\/s12879-023-08217-9","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,18]]},"assertion":[{"value":"13 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The use of de-identified routine data at the Infectious Diseases Institute is approved for analysis and publication by the institutional review board (IRB) of Makerere University College of Health Sciences under the routine care protocol (Approval # 120\u20132009). The institutional review board of Makerere University College of Health Sciences waived the need for informed consent. All methods were performed in accordance with the Declaration of Helsinki and the local guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"L.I, M.J, S.A, and H.I have no conflict of interest to declare.CB is partly supported by the Fogarty International Centre, National Institute of Health (grant# 2D43TW009771-06 \u201cHIV and co-infections in Uganda\u201d).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"238"}}